Frequency of aberrant somatic hypermutation in NLPHL and cHL
. | No. mutated/tested (%) . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Histology . | c-MYC exon 1 . | c-MYC exon 2 . | RhoH/TTF . | PIM1 . | PAX5 . | ||||
| NLPHL; n = 10 | 2/10 (10.0) | 3/9 (33.3) | 1/9 (11.1) | 3/8 (37.5) | 7/9 (77.8)* | ||||
| cHL; n = 9 | 4/9 (44.4) | 1/9 (11.1) | 0/8 (0) | 1/9 (11.1) | 2/9 (22.2) | ||||
. | No. mutated/tested (%) . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Histology . | c-MYC exon 1 . | c-MYC exon 2 . | RhoH/TTF . | PIM1 . | PAX5 . | ||||
| NLPHL; n = 10 | 2/10 (10.0) | 3/9 (33.3) | 1/9 (11.1) | 3/8 (37.5) | 7/9 (77.8)* | ||||
| cHL; n = 9 | 4/9 (44.4) | 1/9 (11.1) | 0/8 (0) | 1/9 (11.1) | 2/9 (22.2) | ||||
Corrected P = .096 (PAX5 mutations in NLPHL compared with cHL). All (4 of 4) hypermutated cases were mixed cellularity. Only 1 of 5 hypermutated cases was nodular sclerosis (P = .025).